Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
NCT04205838 · Jonsson Comprehensive Cancer Center · PHASE2 · terminated · last registry update 2026-02-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “slow accrual” | – | Registry record, Jonsson Comprehensive Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL1R1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-26Also stopped (withdrawn): Meyer Children's Hospital IRCCS, Anakinra + Intravenous Immunoglobulins, Human (NCT06697431)
- 2026-10-08Also stopped (terminated): Heidelberg University, Anakinra (NCT03925194)
- 2026-08-13Also stopped (withdrawn): Kevin McNerney, Anakinra (Kineret®) (NCT06703216)
- 2026-07-16Also stopped (withdrawn): Swedish Orphan Biovitrum, Anakinra (Kineret®) (NCT07706868)
- 2026-06-29Also stopped (withdrawn): Swedish Orphan Biovitrum, Anakinra (NCT06666335)
- 2026-04-02Also stopped (terminated): University Hospital, Caen, PLACEBO + ANAKINRA (NCT02902731)
- 2026-03-05Also stopped (withdrawn): University Health Network, Toronto, Anakinra (Kineret®) (NCT06710197)
- 2026-02-25Results posted on the registry: University of California, San Diego, Atorvastatin and anakinra (NCT04747847)
- 2026-02-20Also stopped (withdrawn): University Hospital, Basel, Switzerland, empagliflozin + anakinra (NCT05174507)
- 2026-02-04Also stopped (suspended): Assistance Publique - Hôpitaux de Paris, Anakinra 100Mg/0.67Ml Inj Syringe + Prednisone (NCT04844814)
- 2026-01-28Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Anakinra, KINERET® (NCT07371689)
- 2025-12-15Phase 3 first posted: Yale University, Anakinra + Tocilizumab (NCT07281027)
- 2025-11-04Results posted on the registry: University of California, San Diego, Infliximab + Anakinra (NCT04898231)
- 2025-10-23Results posted on the registry: Fred Hutchinson Cancer Center, Anakinra (NCT04359784)
- 2025-08-07Results posted on the registry: Virginia Commonwealth University, Anakinra (NCT04017936)
- 2025-08-06Results posted on the registry: Virginia Commonwealth University, Anakinra + Placebo (NCT03797001)
- 2025-06-06Results posted on the registry: Assistance Publique - Hôpitaux de Paris, Anakinra (NCT04341584)
- 2025-05-20Results posted on the registry: Herlev and Gentofte Hospital, Anakinra + Sodium Chloride 9mg/ml Injection (NCT05498467)
- 2025-05-04Results posted on the registry: Marcela V. Maus, M.D.,Ph.D., Anakinra + Axicabtagene Ciloleucel (NCT04150913)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision